As #BloodClotAwarenessMonth comes to an end, we are reminded of the impact of #thrombosis. It can affect anyone, causing serious health complications, including heart attack & #stroke. Chk out our CMO discussing the imp. of raising awareness. 👇  #StopheClot #FactorXI #FactorXIa

#NEWS: #AnthosTx today announced the appt. of Bill Meury as CEO & member of the Board of Directors of @Blackstone Life Sciences-founded Anthos. To read the release, 👉: bit.ly/448tKR4. #afib #stroke #FactorXI #FactorXIa #thrombosis #hemostasis #anticoagulant

A #stroke can occur to anyone, at any age and at any time. Learning and sharing the FAST warning signs can save a life. #AnthosTx applauds the American Heart Association and its efforts to spread awareness. #StrokeAwarenessMonth #StrokeMonth

#AnthosTx extends a special congrats to Dr. David Gailani for being presented w/ 1 of 5 Esteemed Career Awards by @ISTH in 2024, an award given to leaders whose contributions have advanced the scientific community's knowledge & tx of diseases & disorders related to #hemostasis.

Data from the first-ever cost-effectiveness analysis of a #FactorXI inhibitor was presented at the ISPOR meeting. The analysis demonstrated that abelacimab, if approved, could offer significant cost savings compared to a current SOC #anticoagulant. bit.ly/3UMCJnJ

May is #StrokeAwarenessMonth & a reminder to educate people about the risk factors of #stroke. #DYK people w/ #afib are at a 5x higher risk of suffering a stroke? It's critical to understand the FAST warning signs. Learn more from our friends at StopAfib.org & NBCA.

#AnthosTx congratulates Dr. Marc Carrier, who has received the inaugural Outstanding Mentor Award from the @ISTH. Anthos is deeply grateful for your leadership and advice which have helped to guide and shape our #cancerassociatedthrombosis program. #ISTH #ISTH24

#Atrialfibrillation, or #AFib, is an irregular heartbeat that can lead to #bloodclots, heart failure or #stroke. The American Heart Association est. over 12M people will have AFib by 2030. Learn about the risks & warning signs: bit.ly/3QKvMB9. #StrokeAwarenessMonth #StrokeMonth

Land of the free, because of the brave. Today, Anthos Therapeutics proudly honors our nation’s heroes. #ThankYou #MemorialDay

#AnthosTx announced that 84% of all eligible pts, including 75% of pts in the rivaroxaban arm, have transitioned to abelacimab from SOC in the AZALEA-TIMI 71 OLE study of #atrialfibrillation pts at moderate-to-high risk of #stroke. bit.ly/4c7EPV5. cc: TIMI Study Group

#AnthosTx wishes everyone a safe and healthy #July4th. Let us celebrate this #IndependenceDay with gratitude for the freedoms we all enjoy. #FourthofJuly

#FactFriday: Nearly 1 in every 6 strokes is caused by #afib, & these strokes can be 2x as fatal as those unrelated to the condition. Learn more from our friends at NBCA & NBCA 👉: bit.ly/3UFhEKx.

#FactorXI inhibitors offer hope for safe #anticoagulants, potentially protecting against #stroke w/o severe bleeding risks by targeting #thrombosis while preserving #hemostasis. Learn more about the promise of Factor XI from this The Wall Street Journal article: bit.ly/3Twwh2C.

Save the date! Aug. 9-11 for the Get in Rhythm, Stay in Rhythm #AtrialFibrillation Conference by StopAfib.org. Discover patient-centered info & the latest updates in #afib care. See you there! getinrhythm.com

#AnthosTX is headed to @esccardio’s #ESCCongress 2024 where Sid M. Patel from the TIMI Study Group will present periprocedural data from the AZALEA-TIMI 71 study as a late-breaker on Mon. 9/2 @ 10:15 AM ET. bit.ly/3WUUDVe. #FactorXI #atrialfibrillation #afib

Will #FactorXI inhibitors replace #anticoagulants for #stroke prevention in #afib? Read this article by Drs. Sid M. Patel & Christian Ruff from the TIMI Study Group: bit.ly/3T7qa58a. Tune in, 9/2 @ 10:15 ET, for an exciting analysis of the AZALEA study at the #ESCCongress.

Set your alarms! Sid M. Patel from the TIMI Study Group will present periprocedural data from the landmark AZALEA-TIMI 71 #afib study as a late-breaker at @esccardio’s #ESCCongress 2024. Check out the program here 👉: bit.ly/3WUUDVe.

A new analysis from the AZALEA study presented as an #ESCCongress late-breaker by Sid M. Patel w/ the TIMI Study Group found approx. 1% of pts taking abelacimab experienced a major or CRNM bleed while undergoing a procedure. 👉 bit.ly/3z0MiaO.

“For pts taking current SOC #anticoagulants to mitigate their risk of #stroke, it can be frightening to have to stop taking Tx – even temporarily – to undergo any procedure.” Chk out new data from the AZALEA-TIMI 71 study just unveiled at #ESCCongress. 👉 bit.ly/3z0MiaO.

The new periprocedural data debuted @ the #ESCCongress by Dr. Sid M. Patel (TIMI Study Group) builds on the growing body of evidence supporting the potential safety of the novel, investigational, once-monthly, fully human monoclonal antibody #abelacimab. 👉 bit.ly/3z0MiaO.